Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Adaptive Biotechnologies Corporation - Common Stock (NQ:ADPT)

17.11 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Adaptive Biotechnologies Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma
clonoSEQ is now covered to monitor for recurrence in MCL patients who are in treatment-free remission 
From Adaptive Biotechnologies
Via GlobeNewswire
Guess, Tesla, Nvidia And Other Big Stocks Moving Lower In Friday's Pre-Market Session
 
Via Benzinga
Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Analyst Expectations For Adaptive Biotechnologies's Future
 
Via Benzinga
Scholastic Posts Strong Earnings, Joins Ouster, Torrid Holdings, Adaptive Biotechnologies And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma
From Adaptive Biotechnologies
Via GlobeNewswire
Healthcare Stocks Doing Well But SMID Biotech Looking A Little Frazzled
Small caps took another step down this past week as geopolitical events dampened sentiment. 
Via Talk Markets
Topics ETFs Stocks / Equities
Cathie Wood's Ark Invest Loads Up On Beam Therapeutics, Nu Holdings: Offloads MercadoLibre, Adaptive Biotechnologies
 
Via Benzinga
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
Earnings Scheduled For February 11, 2025
 
Via Benzinga
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
From Adaptive Biotechnologies
Via GlobeNewswire
NeoGenomics Is On The Upswing, Reversing A CEO-Tied Sell-Off, On Bullish Long-Term Guidance
The company expects sales to grow 12% to 13% annually in the long term. 
Via Investor's Business Daily
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients
Pairing Adaptive Biotechnologies’ clonoSEQ MRD results with NeoGenomics’ COMPASS and CHART assessment services empowers clinicians and patients with meaningful insights across the treatment continuum 
From Adaptive Biotechnologies
Via GlobeNewswire
Cathie Wood's Ark Invest Trims Palantir Again As Peter Thiel Co-Founded Firm's Stock Tumbles Nearly 15% In 2025
Cathie Wood-led Ark Invest sold 140,518 shares of Palantir and bought shares of Tempus AI Inc. The total value of the trades is about $9.1 million. 
Via Benzinga
Topics Artificial Intelligence
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce
Ark Invest, led by Cathie Wood, made significant trades in 5 companies on Friday: RXRX, ILMN, NTLA, NET, and ADPT. 
Via Benzinga
Topics Workforce
Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025
From Adaptive Biotechnologies
Via GlobeNewswire
Two Big Weeks To Play A Rally In Biotech And Healthcare Stocks
The healthcare sector is lagging over the past year and recent quarter with the XLV flat for 2024 and down over 4% for the recent quarter. 
Via Talk Markets
Topics ETFs Stocks / Equities
Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
Top 3 Health Care Stocks That May Collapse This Quarter
 
Via Benzinga
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting
From Adaptive Biotechnologies
Via GlobeNewswire
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies. 
Via Benzinga
Topics Artificial Intelligence
Smaller Cap Biotechs Are In Season: How Are We Doing?
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range. 
Via Talk Markets
Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma
From Adaptive Biotechnologies
Via GlobeNewswire
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings. 
Via Benzinga
Topics ETFs Stocks
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024
From Adaptive Biotechnologies
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.